From evidence-based medicine to marketing-based medicine: Evidence from internal industry documents

Journal of Bioethical Inquiry

Volumn 7, Issue 1, 2010, Pages 13-29

  Spielmans, Glen I ^a   Parry, Peter I ^b  

^a METROPOLITAN STATE UNIVERSITY   (United States)

^b FLINDERS UNIVERSITY   (Australia)

Author keywords

Evidence based medicine; Marketing; Marketing based medicine; Olanzapine; Pharmaceutical industry; Quetiapine

Indexed keywords

EID: 77949304855     PISSN: 11767529     EISSN: 18724353     Source Type: Journal    
DOI: 10.1007/s11673-010-9208-8     Document Type: Article

References (95)

1. Alam, E. S. K., and L. Jeffries. 2008. Discussion document: Seroquel/Seroquel XR and weight gain. AstraZeneca document available from authors.
2. Angell, M. 2008. Industry-sponsored clinical research: A broken system. Journal of the American Medical Association 300: 1069-1071.
3. Applbaum, K. 2008. Where supply meets demand: Comorbidity and channel stabilization in the creation of a psychopharmaceutical blockbuster. Paper presented at the Rethinking Economic Anthropology conference, January, in London, UK. Available: http://www. rethinkingeconomies. org. uk/web/d/doc_62. pdf (Accessed March 10, 2008).
4. Arvanitis, L. 1997. Weight gain (email). Retrieved March 3 2009 from http://www. furiousseasons. com/zip/seroqueldocs. zip.
5. AstraZeneca. 2000. Seroquel (quetiapine) commercial support team technical document (TD004): BPRS meta-analysis. Retrieved March 3, 2009, from http://www. furiousseasons. com/zip/seroqueldocs. zip.
6. AstraZeneca. 2001. Seroquel (quetiapine) speakers slide kit. AstraZeneca document available from authors.
7. AstraZeneca. 2003. Untitled. Retrieved March 3, 2009, from http://www. furiousseasons. com/zip/seroqueldocs. zip.
8. Aubuchon, N. W. 2002. Re: Request (email). Retrieved February 15, 2007, from http://www.furiousseasons.com/zyprexa%20documents/ZY201381347.pdf.
9. Baker, R. W. 2000. Meeting with endocrinologic consultants (email). Retrieved February15, 2007, from http://www. furiousseasons. com/zyprexa%20documents/ZY100378053. pdf.
10. Bandick, M. 2001. Zyprexa primary care presentation. Retrieved February 15, 2007, from http://www.furiousseasons.com/zyprexa%20documents/ZY100041630.pdf.
11. BBC. 2007. Panorama: Secrets of the drugs trials. Retrieved March 30, 2007, from http://news.bbc. co.uk/2/hi/programmes/panorama/6317137.stm.
12. Berk, M., L. Berk, K. Moss, S. Dodd, and G. S. Malhi. 2006. Diagnosing bipolar disorder: How can we do it better? Medical Journal of Australia 184: 459-462.
13. Brecher, M., I. W. Rak, K. Melvin, and A. M. Jones. 2000. The long-term effect of quetiapine (Seroquel) monotherapy on weight in patients with schizophrenia. International Journal of Psychiatry in Clinical Practice 4: 287-291.
14. Breier, A. 1999. Olanzapine-associated weight changes (email). Retrieved February 15, 2007, from http://www.furiousseasons.com/zyprexa%20documents/ZY1%20%20%2000008867.pdf.
15. Brodie, T. M. 2000. Re: Meeting with endocrinologic consultants (email). Retrieved February 15, 2007, from http://www.furiousseasons.com/zyprexa%20documents/ZY100378054.pdf.
16. Carlson, G. A. 2009. Treating the childhood bipolar controversy: A tale of two children. American Journal of Psychiatry 166: 18-24.
17. Cavazzoni, P. 2002a. Re: ZYP: Diabetic coma and neuroleptic malignant syndrome (case no. 200201953) (email). Retrieved February 15, 2007, from http://www. furiousseasons. com/zyprexa%20documents/ZY201797499. pdf.
18. Cavazzoni, P. 2002b. MHLW PI (email). Retrieved February 15, 2007, from http://www.furiousseasons. com/zyprexa%20documents/ZY200388811. pdf.
19. Chan, A.-W. 2008. Bias, spin, and misreporting: Time for full access to trial protocols and results. PLoS Medicine 5: e230.
20. Clary, C. 2000. Zoloft: PSC update. Pfizer document available from authors.
21. Current Medical Directions. 1999. Worldwide publications status update. Retrieved May 27, 2007, from http://healyprozac. com/GhostlyData/zoloftpublications. htm.
22. Dawdy, P. 2008, April 2. Bitter pill. Willamette Week. Available at: http://wweek. com/editorial/3421/10752/.
23. Dianthus Medical. Undated. Untitled. Retrieved September 21, 2009, from http://dianthus. co. uk/our-services/medical-writing/medical-communications/manuscripts-for-publication.
24. Edwards, J. 2009a. CASPERR was GSK's friendly ghostwriting program on Paxil. Retrieved September 18, 2009, from http://industry. bnet. com/pharma/10003807/cassper-was-gsks-friendly-ghostwriting-program-on-paxil/.
25. Edwards, J. 2009b. Email: AstraZeneca knew in 1997 that Seroquel caused weight gain. Retrieved March 5, 2009, from http://industry. bnet. com/pharma/10001228/e-mail-astrazeneca-knew-in-1997-that-seroquel-caused-weight-gain/.
26. Eli Lilly. 1994. Olanzapine lifeplan. Retrieved February 15, 2007, from http://www. furiousseasons. com/zyprexa%20documents/ZY100035541. pdf.
27. Eli Lilly. 1995. The third United States schizophrenia advisory panel meeting. Retrieved February 15, 2007, from http://www. furiousseasons. com/zyprexa%20documents/ZY100426128. pdf.
28. Eli Lilly. 2000a. Note from one of our speakers about Zyprexa and primary care. Retrieved February 15, 2007, from http://www. furiousseasons. com/zyprexa%20documents/ZY100629260. pdf.
29. Eli Lilly. 2000b. Untitled. Retrieved February 15, 2007, from http://www. furiousseasons. com/zyprexa%20documents/ZY100175585. pdf.
30. Eli Lilly. 2001a. Global positioning strategic imperatives and tactical directions: Final report. Retrieved September 1, 2009, from http://zyprexalitigationdocuments. com/%5Cdocuments%5CConfidentiality-Challenge%5CDocs-challenged-in-10-3-list%5C56-ZY71561134. pdf.
31. Eli Lilly. 2001b. Hyperglycemia/diabetes data on demand resource guide. Retrieved February 15, 2007, from http://www. furiousseasons. com/zyprexa%20documents/ZY202417638. pdf.
32. Eli Lilly. 2001c. Zyprexa product team off-site. Retrieved February 15, 2007, from http://www. furiousseasons. com/zyprexa%20documents/ZY201548768. pdf.
33. Eli Lilly. 2002a. Janssen meeting feedback-Chris Fear. Retrieved February 15, 2007, from http://www. furiousseasons. com/zyprexa%20documents/ZY200399435. pdf.
34. Eli Lilly. 2002b. Managed care-June 2002. Retrieved February 15, 2007, from http://www. furiousseasons. com/zyprexa%20documents/ZY200083405. pdf.
35. Eli Lilly. 2002c. Zyprexa (olanzapine) brand council III: Zyprexa US 2003-2004 marketing and business. Retrieved September 2, 2009, from http://zyprexalitigationdocuments. com/%5Cdocuments%5CConfidentiality-Challenge%5CDocs-challenged-in-10-3-list%5C123-ZY203452219. pdf.
36. Eli Lilly. 2003. CSF # 1 review. Retrieved February 15, 2007, from http://www. furiousseasons. com/zyprexa%20documents/ZY200506745. pdf.
37. Eli Lilly. 2004. Weight task force. Retrieved February 15, 2007, from http://www. furiousseasons. com/zyprexa%20documents/ZY200523684. pdf.
38. Eli Lilly. Undated-a. Medical press: Pre-launch feature outline. Retrieved August 20, 2009, from http://zyprexalitigationdocuments. com/%5Cdocuments%5CConfidentiality-Challenge%5CDocs-challenged-in-10-3-list%5C145-ZY200187608-7614. pdf.
39. Eli Lilly. Undated-b. Key player playbook. Retrieved February 15, 2007, from http://www. furiousseasons. com/zyprexa%20documents/ZY100174816. pdf.
40. Eli Lilly. Undated-c. Weight gain management marketing verbatims. Retrieved February 15, 2007, from http://www. furiousseasons. com/zyprexa%20documents/ZY100040198. pdf.
41. Eli Lilly. Undated-d. Olanzapine core medical efficacy and safety beliefs. Retrieved February 15, 2007, from http://www. furiousseasons. com/zyprexa%20documents/ZY100592565. pdf.
42. Eli Lilly. Undated-e. Adverse reactions. Retrieved February 15, 2007, from http://www. furiousseasons. com/zyprexa%20documents/ZY100379985. pdf.
43. Eli Lilly. Undated-f. Regulatory activity. Retrieved February 15, 2007, from http://www. furiousseasons. com/zyprexa%20documents/ZY100386523. pdf.
44. Eli Lilly. Undated-g. Zyprexa retail implementation guide. Retrieved February 15, 2007, from http://www. furiousseasons. com/zyprexa%20documents/ZY100040668. pdf.
45. Elsevier. 2007. Pharma solutions: The preferred medical publishing partner for healthcare worldwide. Document available from author.
46. Feather, K. R. 1996. Re: NDA20-592. Retrieved February 15, 2007, from http://www. furiousseasons. com/zyprexa%20documents/ZY100074131. pdf.
47. Flanagin, A., L. A. Carey, P. B. Fontanarosa, S. G. Phillips, B. P. Pace, G. D. Lundberg, et al. 1998. Prevalence of articles with honorary authors and ghost authors in peer-reviewed medical journals. Journal of the American Medical Association 280: 222-224.
48. GlaxoSmithKline. Undated. Effect of Paxil CR tablets and Paxil tablets on suicidal ideation and behavior in adults. Retrieved May 10, 2009, from http://www. gsk. com/media/paroxetine/Paxil-CR-and-Paxil-Adult-Suicide. pdf.
49. Glenmullen, J. 2007. Untitled. Retrieved March 13, 2008, from http://finance. senate. gov/press/Gpress/2008/prg061208a. pdf.
50. Goldberg, J. F., J. L. Garno, A. M. Callahan, D. L. Kearns, B. Kerner, and S. H. Ackerman. 2008. Overdiagnosis of bipolar disorder among substance use disorder inpatients with mood instability. Journal of Clinical Psychiatry 69: 1751-1757.
51. Hagger, S. 2003. IIT benchmarking report (email). Retrieved September 2, 2009, from http://www. healthyskepticism. org/documents/documents/IIT-Seroquel. pdf.
52. Hawkins, Z. 2001. To all sales representatives selling Paxil (memo). Retrieved August 10, 2009, from http://www. healthyskepticism. org/documents/documents/20010816Hawkinstoreps. pdf.
53. Healy, D. 2006. The latest mania: Selling bipolar disorder. PLoS Medicine 3: e185.
54. Healy, D., and D. Cattell. 2003. Interface between authorship, industry and science in the domain of therapeutics. British Journal of Psychiatry 183: 22-27.
55. Healy, D., and J. Le Noury. 2007. Pediatric bipolar disorder: An object of study in the creation of an illness. International Journal of Risk & Safety in Medicine 19: 209-221.
56. Hofland, P. Undated. Optimizing brand success through effective publication planning & management. Retrieved September 21, 2009, from http://sunvalleycommunication. com/Documents/Optimizing%20Publication%20Planning%20Introduction_va. ppt.
57. Hough, N. 1999. Re: ECNP abstract 'weight gain & diabetes management' (email). Retrieved March 3, 2009, from http://www. furiousseasons. com/zip/seroqueldocs. zip.
58. Jefferson T., M. Rudin, S. Brodney Folse, F. Davidoff. 2007. Editorial peer review for improving the quality of reports of biomedical studies. Cochrane Database of Systematic Reviews 2.
59. Jureidini, J. N., L. B. McHenry, and P. R. Mansfield. 2008. Clinical trials and drug promotion: Selective reporting of study 329. International Journal of Risk & Safety in Medicine 20: 73-81.
60. Keller, M. B., N. D. Ryan, M. Strober, R. G. Klein, S. P. Kutcher, B. Birmaher, et al. 2001. Efficacy of paroxetine in the treatment of adolescent major depression: A randomized, controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry 40: 762-772.
61. Kerr, J. G. 2002. Re: Japan: Glucose-teleconference review (email). Retrieved February 15, 2007, from http://www. furiousseasons. com/zyprexa%20documents/ZY200388761. pdf.
62. Kinon, B. 1998. Re: Wishing/Goldstein articles (email). Retrieved February 15, 2007, from http://www. furiousseasons. com/zyprexa%20documents/ZY100095495. pdf.
63. Lexchin, J., L. A. Bero, B. Djulbegovic, and O. Clark. 2003. Pharmaceutical industry sponsorship and research outcome and quality: Systematic review. British Medical Journal 326: 1167-1170.
64. Mathieu, S., I. Boutron, D. Moher, D. G. Altman, and P. Ravaud. 2009. Comparison of registered and published primary outcomes in randomized controlled trials. Journal of the American Medical Association 302: 977-984.
65. McHenry, L. B., and J. N. Jureidini. 2008. Industry-sponsored ghostwriting in clinical trial reporting: A case study. Accountability in Research 15: 152-167.
66. Moffat, B., and C. Elliott. 2007. Ghost marketing: pharmaceutical companies and ghostwritten journal articles. Perspectives in Biology and Medicine 50: 18-31.
67. Moreno, C., G. Laje, C. Blanco, H. Jiang, A. B. Schmidt, and M. Olfson. 2007. National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. Archives of General Psychiatry 64: 1032-1039.
68. Mowatt, G., L. Shirran, J. M. Grimshaw, D. Rennie, A. Flanagin, V. Yank, et al. 2002. Prevalence of honorary and ghost authorship in Cochrane reviews. Journal of the American Medical Association 287: 2769-2771.
69. Moynihan, R., I. Heath, and D. Henry. 2002. Selling sickness: The pharmaceutical industry and disease mongering. British Medical Journal 324: 886-891.
70. Olson, J. 2009. U doctor scrutinized over drug research. St. Paul Pioneer Press. 18 March.
71. Paris, J. 2009. The bipolar spectrum: A critical perspective. Harvard Review of Psychiatry 17: 206-213.
72. Phoenix International Research. 2000. Awareness of diabetes in association with antipsychotics. Retrieved February 15, 2007, from http://www. furiousseasons. com/zyprexa%20documents/ZY100375967. pdf.
73. Ross, J. S., K. P. Hill, D. S. Egilman, and H. M. Krumholz. 2008. Guest authorship and ghostwriting in publications related to rofecoxib: A case study of industry documents from rofecoxib litigation. Journal of the American Medical Association 299: 1800-1812.
74. Sackett, D. L., W. M. C. Rosenberg, J. A. M. Gray, R. B. Haynes, and W. S. Richardson. 1996. Evidence based medicine: What it is and what it isn't. British Medical Journal 312: 71-72.
75. Scarpuzza, J. Undated. Scientific publications build brand success. Retrieved September 23, 2009, from http://www. ngpharma. com/article/Scientific-Publications-Build-Brand-Success/.
76. Sismondo, S. 2007. Ghost management: How much of the medical literature is shaped behind the scenes by the pharmaceutical industry? PLoS Medicine 4: e286.
77. Smith, R. 2005. Medical journals are an extension of the marketing arm of pharmaceutical companies. PLoS Medicine 2: e138.
78. Smith, R. 2006. Lapses at the New England Journal of Medicine. Journal of the Royal Society of Medicine 99: 380-382.
79. SmithKlineBeecham. Undated. CASPERR: Case study publications for peer review. Unpublished manuscript.
80. Spielmans, G. I. 2009. The promotion of olanzapine in primary care: An examination of internal industry documents. Social Science & Medicine 69: 14-20.
81. Steinman, M. A., L. A. Bero, M. M. Chren, and C. S. Landefeld. 2004. Narrative review: The promotion of gabapentin: an analysis of internal industry documents. Annals of Internal Medicine 145: 284-293.
82. Sunvalley Communication. Undated. Writing and editorial services. Retrieved September 21, 2009, from http://sunvalleycommunication. com/writingandeditorial. aspx.
83. Tollefson, G. D. 1997. Zyprexa product team 4 column summary. Retrieved February 15, 2007, from http://www. furiousseasons. com/zyprexa%20documents/ZY200270343. pdf.
84. Tumas, J. 1999. Re: 2 EPS abstracts for APA. Retrieved February 29, 2009, from http://www. furiousseasons. com/zip/seroqueldocs. zip.
85. Tumas, J. 2000. FW: Meta analyses (email). Retrieved February 28, 2009, from http://www. furiousseasons. com/zip/seroqueldocs. zip.
86. Turner, E. H., A. M. Matthews, E. Linardatos, R. A. Tell, and R. Rosenthal. 2008a. Selective publication of antidepressant trials and its influence on apparent efficacy. New England Journal of Medicine 358: 252-260.
87. Turner, E. H., A. M. Matthews, E. Linardatos, R. A. Tell, and R. Rosenthal. 2008b. Supplement to: Selective publication of antidepressant trials and its influence on apparent efficacy. Retrieved January 19, 2008, from http://content. nejm. org/cgi/data/358/3/252/DC1/1.
88. Velligan, D. I., J. Newcomer, J. Pultz, J. Csernansky, A. L. Hoff, R. Mahurin, et al. 2002. Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophrenia Research 53: 239-248.
89. Ventura County Behavioral Health Department. 1999. Untitled. Retrieved February 15, 2007, from http://www. furiousseasons. com/zyprexa%20documents/ZY201016928. pdf.
90. Villarroel, E. P. 2007. March Master plan: The making of a successful publication strategy. PharmaVOICE, 1-5.
91. Washburn, J. 2005. Rent-a-researcher. Slate. Retrieved February 10, 2007 from: http://www. slate. com/id/2133061/.
92. White, H. 2001. RE: Publication date for Paroxetine Adolescent Depression Study (email). Document available from authors.
93. Whittington, C. J., T. Kendall, P. Fonagy, D. Cottrell, A. Cotgrove, and E. Boddington. 2004. Selective serotonin reuptake inhibitors in childhood depression: Systematic review of published versus unpublished data. Lancet 363: 1341-1345.
94. Williamson, D. 2002. Re: Clinical summary update (email). Retrieved February 15, 2007, from http://www. furiousseasons. com/zyprexa%20documents/ZY200540696. pdf.
95. Zimmerman, M., C. J. Ruggero, I. Chelminski, and D. Young. 2008. Is bipolar disorder overdiagnosed? Journal of Clinical Psychiatry 69: 935-940.